HealthLeaders Media March 26, 2024
Marie DeFreitas

Some states are hesitant to cover the popular drugs.

Weight loss drugs have soared in popularity; while some states have been hesitant to cover them, others have not. A recent JAMA study found that five states offer unrestricted coverage of GLP-1 drugs Wegovy and Saxenda that were approved for weight loss.

The data from this study comes from formularies for 47 state Medicaid programs from the first quarter of 2023.

The study found that a total of ten states cover Saxenda or Wegovy for weight loss, while five of those states offered restricted access through...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Govt Agencies, Insurance, Medicaid, Patient / Consumer, Pharma / Biotech, Provider, States, Survey / Study, Trends
Related Articles:
New Florida law allowing C-sections outside hospitals could be national model
Pulling Out the Rug on Informed Consent — New Legal Threats to Clinicians and Patients
State-by-state breakdown of resident physician unions
Recent Proposed Indiana Legislation and Executive Order Would Place New Requirements on Nonprofit Hospitals
The New York Health Law with Dramatic Implications for Insurance Carriers and Brokers

Share This Article